AllianceBernstein’s Capricor Therapeutics CAPR Stock Holding History

AllianceBernstein’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.74M	Buy	57,300 +16,870	+42%	+$512K	﹤0.01%	2121
2026 Q1	$1.17M	Buy	40,430 +1,600	+4%	+$42.6K	﹤0.01%	2271
2025 Q4	$1.12M	Sell	38,830 -39,890	-51%	-$521K	﹤0.01%	2289
2025 Q3	$568K	Hold	78,720	–	–	﹤0.01%	2615
2025 Q2	$782K	Buy	78,720 +65,440	+493%	+$691K	﹤0.01%	2415
2025 Q1	$126K	Hold	13,280	–	–	﹤0.01%	3028
2024 Q4	$183K	Buy	+13,280	New	+$233K	﹤0.01%	3040
2015 Q4	–	Sell	-1,000	Closed	-$41K	–	2924
2015 Q3	$41K	Buy	+1,000	New	+$44.5K	﹤0.01%	2919

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein's CAPR Position: Q2 2026 in Review

AllianceBernstein increased its Capricor Therapeutics (CAPR) stake by 42% in Q2 2026, buying an estimated $512K and bringing the position to 57,300 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #2121.

AllianceBernstein first reported a position in CAPR in Q3 2015 and has held it in 8 quarters since. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

AllianceBernstein held 57,300 shares of Capricor Therapeutics worth $1.74M as of Q2 2026.
AllianceBernstein bought 16,870 Capricor Therapeutics shares in Q2 2026, an estimated $512K.
Capricor Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2121 holding.
AllianceBernstein first reported a position in Capricor Therapeutics in Q3 2015 and has held it in 8 quarters since.
170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.